NYMOX PHARMACEUTICAL CORPORATION (NYMXF) Capital expenditures 2016–2024
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$0FY2024 · since FY2016: $2,000 → $0
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $0 | -100.0% |
| FY2023 | $3,000 | — |
| FY2022 | $0 | -100.0% |
| FY2021 | $6,000 | -53.8% |
| FY2020 | $13,000 | — |
| FY2019 | $0 | -100.0% |
| FY2018 | $36,000 | — |
| FY2016 | $2,000 | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More NYMXF financial trends
NYMXF RevenueNYMXF Net incomeNYMXF Net marginNYMXF Gross profitNYMXF Gross marginNYMXF Operating incomeNYMXF Operating marginNYMXF Operating cash flowNYMXF Free cash flowNYMXF Return on equityNYMXF Stock buybacksNYMXF Dividends paidNYMXF Total assetsNYMXF Total liabilitiesNYMXF Shareholders’ equityNYMXF overview →